

# STATE OF THE MARKET

EVERCORE | Private  
Funds Group



VIRES ACQUIRIT EUNDO

# EVERCORE

The contents of this document are not provided for any person other than those specified below including, without limitation, any retail persons.

This document must not be copied, reproduced, published, distributed, disclosed or passed to any other person, directly or indirectly, in whole or in part, by any person, through any medium or in any form, at any time without the formal written authorisation of Evercore Partners International LLP (“Evercore”). By accepting this document, the recipient agrees to be bound by the obligations and limitations in this disclaimer.

This document has been prepared using materials and information that were made available to Evercore and other organisations that have authored articles herein from publicly available sources. In writing the content of this document, Evercore and the other organisations that have authored articles herein may have assumed and relied upon the accuracy and completeness of any financial and other information and data they have used without independent verification of such information or data.

This document does not purport to be comprehensive or exhaustive or contain all the information that a recipient may need in order to evaluate or act on any of the matters disclosed within it. This document speaks as of the date hereof and has not been independently verified and no representation or warranty, express or implied, is made as to the accuracy or completeness or sufficiency of such information and nothing contained herein is, or may be relied upon as, a representation, whether as to the past, the present or the future. Each of Evercore, its affiliates and their respective directors, officers, employees, agents, representatives, affiliates and/or advisers expressly disclaims any obligations or undertaking to update or verify any such information.

This document is necessarily based upon economic, market and other conditions as Evercore believes to be in effect on, and the information made available to Evercore as of, the date hereof. There are a number of risks, uncertainties and factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance cannot and should not be relied on as a guide to future performance. To the maximum extent permitted by law, and except in the case of fraud, Evercore, its affiliates and their respective directors, officers, employees and agents expressly disclaim any liability which may arise from this document and any information contained within it, or any other written or oral information provided in connection therewith, and any errors, misrepresentation or misstatement contained therein and/or omissions therefrom.

This document has been prepared for information purposes only and is not to be construed as an offer or invitation or solicitation or recommendation or provision of advice to sell or purchase any securities or conduct any other investment activity or transaction and is not a commitment by Evercore (or any of its affiliates or their respective officers, employees, representatives or agents or advisers) to provide or arrange any financing or other service for any transaction or to purchase or sell any security or other investment in connection therewith.

This document may not reflect information known to other professionals in other business areas of Evercore and its affiliates.

By accepting this document, the recipient acknowledges and agrees that Evercore does not and will not act in a fiduciary capacity for the recipient. Evercore may only be regarded by any recipient as acting on its behalf as financial adviser or otherwise following the execution of an engagement letter between us on mutually satisfactory terms.

Evercore and its affiliates do not provide legal, accounting or tax advice. Accordingly, any statements contained herein as to tax, legal or accounting matters are neither written nor intended by Evercore or its affiliates to be used and cannot be used by any taxpayer for the purpose of avoiding tax that may be imposed on such taxpayer. Each person should seek legal, accounting and tax advice based on his, her or its particular circumstances from independent advisors regarding the impact of the information or matters described herein.

This document should not be viewed as advice or recommendations with respect to any particular investment or investment strategy. This document contains articles written by Evercore employees and by third parties. All third-party articles were written specifically for this issue, and any data or viewpoints contained in any third-party articles belong solely to their authors, may not reflect the viewpoints or authorship of Evercore or its affiliates, and in no way shall Evercore or its affiliates be held liable or responsible for them. Any views or opinions expressed herein reflect the judgment at this date of the respective authors and are subject to change without notice.

Where Evercore or an affiliate is licensed in a jurisdiction, the recipient of this document shall consider such distribution to have come from only from the relevant licensed Evercore entity (ies). Notwithstanding the foregoing, this document is not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any jurisdiction (including the United Kingdom) where such distribution, publication, availability or use would be contrary to applicable law or regulation or which would subject Evercore and/or its subsidiaries or affiliates to any registration or licensing requirements in such jurisdiction.

The distribution of this document and its contents in jurisdictions other than the United Kingdom may be restricted by law and, accordingly, recipients of this document represent to Evercore that they are able to receive this document without contravention of any legal, registration or regulatory requirements in the jurisdiction in which they reside or conduct business, or any requirement for Evercore and/or its affiliates to undergo any registration or licensing requirements in such jurisdiction. Recipients of this document outside of the United Kingdom should inform themselves about and observe any applicable legal restrictions in their jurisdiction which may be relevant to the distribution, possession or use of this document and recognise that Evercore does not accept any responsibility for contravention of any legal restrictions in such jurisdiction or which are otherwise applicable to such recipient.

To the extent this document or any statement contained within it constitutes a financial promotion which is not exempt for the purposes of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (the “Order”), this document is only being distributed and delivered to certain persons in the United Kingdom on the basis that such person falls within one of the exemptions contained in the Order. The contents of this document have accordingly not been approved by an authorised person for the purposes of Section 21 of the Financial Services and Markets Act 2000 (“FSMA”). Such approval of this document would be required by Section 21 FSMA if the exemptions referred to below, or some other exemption, did not apply. This document and its contents are being distributed and delivered on a confidential basis only to persons in the United Kingdom who are (or who are reasonably believed to be):

- (i) a person having professional experience in matters relating to investments as defined in Article 19 of the Order; or
- (ii) a high net worth company or trust or other person of the kind to which Article 49(2) of the Order applies; or
- (iii) any other person to whom it may otherwise be lawfully communicated in accordance with the Order.

Any investment or investment activity to which this document or information relates is available only to such persons as are referred to in the paragraph above and will be engaged in only with such persons. Persons not falling within these categories should not rely or act upon this document or any information contained within it. If you have received this document and you are not such a person you should immediately return it to Evercore. Otherwise you will be deemed to have warranted that you are such a person, or are otherwise a person to whom such information may be lawfully distributed and delivered by Evercore.

Evercore, its affiliates and their respective directors, officers, employees, agents, representatives and/or advisers shall not be responsible for any costs or expenses incurred by any recipient of this document in connection with the appraisal of it or its content and/or for any other costs and expenses incurred by such recipient.

Any matter, claim or dispute arising out of or in connection with this document or its contents, whether contractual or non-contractual, is to be governed by and determined in accordance with English law and the recipient, by accepting delivery of this document, agrees that the courts of England shall have exclusive jurisdiction to resolve any dispute, whether contractual or non-contractual, arising out of or in connection with it or its contents.

© Evercore. All rights reserved. This presentation is confidential and proprietary to Evercore. Evercore accepts no liability for the actions of third parties in relation to the redistribution of the material in this document.

# The importance of healthcare as an investment sector

BY JO NATAURI, FOUNDER OF INVIDIA CAPITAL MANAGEMENT

**T**he US healthcare sector, valued at over \$4.5 trillion and projected to make up nearly 20% of the nation's GDP by 2031,<sup>1</sup> is not only a cornerstone of the economy but also a dynamic space for innovation and investment. This sector's significance spans personal, political and societal dimensions, attracting sustained private equity interest, which has tripled in the past decade. As an industry that has historically outperformed other sectors across economic cycles, healthcare remains an attractive area of investment with potential to drive large-scale change and improve millions of lives across the US.

Over the past decade, private equity investments in healthcare have grown threefold, driven by new market dynamics and innovations, catalysed by the pandemic.<sup>2</sup> These changes have introduced a multitude of fresh opportunities, bringing a wave of accelerated innovation across the industry not just in terms of products, but also in healthcare delivery services driven by the adoption of new technologies. The attraction of investing in healthcare is only matched by the complexity of a highly diverse industry where multiple constituents and regulatory considerations often drive outcomes.

Invidia Capital Management was founded in 2024 to harness these long-term investment opportunities emerging within the healthcare sector. Based in New York, Invidia is a healthcare-focused private equity firm specialising in mid-market investments across North America. Under the leadership of Jo Natauri, formerly Global Head of Private Healthcare Investing at Goldman Sachs, Invidia has been established with a vision to build a world-class firm committed to advancing healthcare through strategic investments and a culture of integrity. Guided by a team of seasoned healthcare experts, Invidia's approach aims to drive impactful value for patients, providers and payors alike, aligning with the firm's mission to bring meaningful improvements to the complex healthcare ecosystem. By investing in healthcare's evolving landscape, Invidia seeks to unlock opportunities created

by sustained innovation and increasing demand.

## **Innovation and permanent demand supports long-term healthcare thesis**

The healthcare sector's sustained innovation and permanent demand create a strong foundation for long-term investment opportunities. According to the US Bureau of Economic Analysis, healthcare innovation accounts for at least 18% of real per capita growth.<sup>2,3</sup> Biopharma research and development ("R&D") spending also demonstrated a compound annual growth rate ("CAGR") of 12% worldwide and 15% in the US from 1986 to 2023.<sup>4</sup> Declines in R&D spending during economic downturns have generally been short-lived. In terms of costs, since 1990, nursing, healthcare technology and home healthcare professions have experienced consistent growth (excluding 2020) driven by underlying healthcare demand increases.<sup>5</sup> Health insurance premiums for workers and employers increased by 4% per year from 2013 to 2023, with 65% of US workers covered by self-funded plans, up from about 50% in 2000.<sup>6</sup> Looking ahead, healthcare profit pools are expected to grow from \$583 billion in 2022 to \$819 billion by 2027, a CAGR of 7%.<sup>7</sup> Inflation is also projected to increase healthcare spending by more than 4% through to 2032.<sup>8</sup>

Innovation is essential for improving health outcomes, but, within healthcare, it is often a lengthy and costly endeavor. A recent study estimated that the average cost of developing a new drug is nearly \$900 million, accounting for failures and capital costs.<sup>9</sup> With only an 8% success rate in clinical trials, the risk of commercial success remains high, even when new drugs show safety and efficacy.<sup>10</sup> By supporting these companies, investors help ensure that potentially transformative therapies have sufficient funding to achieve their promise, driving improved health outcomes.

## **The complex nature of the healthcare sector is primed for PE-driven transformation**

Despite increased healthcare spending, the US continues to lag in health outcomes.<sup>2</sup> A report from the Commonwealth Fund

ranks the US last among ten peer countries based on five key metrics: access to care, care process, administrative efficiency, equity and health outcomes.<sup>2</sup> A significant cause of this disconnect is the fragmented nature of the country's healthcare system, composed of multiple, independent care networks, insurers, payors and benefit managers leading to increased friction for patients navigating the system.

The complexity of the US healthcare system leads to inefficiencies in data sharing, which drive up costs and increase the risk of medical errors. For example, compliance with the Health Insurance Portability and Accountability Act (HIPAA) regulations costs approximately \$8.3 billion annually, yet the regulations have done little to facilitate effective data sharing among patients and providers.<sup>11</sup> Organisations that fail to comply with regulations face additional costs, averaging \$10 million.<sup>11</sup> Provider shortages, largely driven by burnout from excessive administrative burdens and record-keeping requirements, also reduce access to care. In a recent survey, 53% of US physicians reported feeling burnt out and 23% exhibited signs of depression, with both trends worsening since the Covid-19 pandemic.<sup>12,13</sup> The increasing demand for cost-effective and outcome-improving solutions creates significant opportunities. However, identifying the right ones that can deliver real value and achieve the healthcare improvements we need remains challenging. Understanding key trends can guide investors toward opportunities for true value creation by unlocking either product or service expansion.

Given the complexity of the industry, Invidia has assembled a distinguished set of Senior Advisers and a broader executive network comprised of healthcare leaders to provide strategic input and guidance on navigating the sector. Between these two groups and the team's broader individual networks, Invidia has developed a diverse set of connections across the sector, built over decades of the team's experience and a large number of transactions at prior firms. In so doing, Invidia intends to focus on investment opportunities underpinned by long-term,

sustainable growth trends within healthcare. The four primary focus areas of opportunity are:

**1. Supporting R&D and innovation:** Investing in companies that drive science and R&D in healthcare, underpinned by a belief in the sector's perpetual demand for innovation. This area allows Invidia to strive to capitalise on advancements in science that will continue to shape healthcare in the long term.

**2. Tech-enabled services:** While healthcare is resistant to direct tech disruption, Invidia believes that tech-enablement enhances efficiency, diagnosis and patient outcomes, making this area ripe for growth.

**3. Delivery transformation:** Changes in where and how healthcare is delivered have accelerated post-Covid-19. With financial pressure on hospitals and shifts in patient preferences, Invidia believes that opportunities exist in areas like outpatient services, telehealth and urgent care centres that offer lower-cost and accessible alternatives.

**4. Consumer-oriented healthcare:** As healthcare costs rise, consumers are increasingly responsible for their care choices and costs. This shift can create opportunities in sectors focused on consumer-driven healthcare solutions, including digital health and at-home diagnostics.

Long-term tailwinds, including continued R&D spending and innovation potential, position these target sub-sectors for sustainable growth.

### Continued adoption of technology will transform healthcare

Rapid innovation in the technology sector, especially as it relates to utilisation of large data sets, are expected to continue to have an outsized impact on the healthcare industry. Currently, about 30% of all data generated worldwide is healthcare-related and health data is expected to grow faster than in other sectors.<sup>14</sup> Big data approaches are improving the efficiency and accuracy of disease diagnosis, drug development and the identification of factors that influence therapy response. However, challenges in healthcare data collection, storage and sharing create inefficiencies and increase the risk of medical errors. Innovative solutions leveraging artificial intelligence ("AI") and machine learning offer significant potential to address these issues. Yet, the feasibility of deploying tech-based solutions across the healthcare ecosystem remains uncertain. On average, hospitals use 16 different electronic health record systems across affiliated practices and 98% of referrals are still done by fax, despite the availability of electronic options.<sup>15, 16</sup> Entrenched behaviours,

resistance to change and the learning curve associated with new systems can limit the real-world value of innovation. Investing in companies that not only develop solutions for healthcare needs but also have strategies to drive adoption can be key to delivering quality care for patients and improving provider productivity.

### Opportunities in a post-pandemic healthcare landscape

The Covid-19 pandemic accelerated provider burnout, exacerbated primary care and nursing shortages and led to hospital closures, especially in rural and low-income areas. While these challenges hinder access to timely and effective care, they also present opportunities for companies that can address these issues. Outsourcing equipment, for instance, can help reduce capital expenditures and improve health equity. A mobile MRI unit that travels between facilities can increase access to imaging technology at a cost that is lower than installing systems in multiple locations. Additionally, approaches that enable home-based care, telemedicine and care delivery in retail settings are poised for growth. Prior to the pandemic, only about 1% of medical and behavioural health visits were conducted virtually; today, that figure stands at 25%.<sup>17</sup> The at-home diagnostic testing market has also grown, now valued at \$45.6 billion, and is expected to expand by over 10% annually through 2031.<sup>18</sup> Private equity investors appear to have an opportunity to achieve substantial return on investment ("ROI") by supporting companies that leverage virtual communication to increase access, enhance patient-provider interactions, improve adherence to treatment and expand care delivery beyond traditional clinical settings.

### Conclusion

In addition to the growth in healthcare-related spending and investment, there are multiple underlying tailwinds that private equity investors should consider: the ageing population, increasing incidence of chronic disease and persistent health inequities. Supporting companies that facilitate interconnectivity across the healthcare landscape, create new care delivery and payment models and enable safer, more effective health interventions is important for addressing these challenges. These initiatives also create exciting opportunities for investors such as Invidia, who have the experience to assess the complexities of the regulatory environment and the specific technologies needed to achieve these goals. With this understanding, private equity investors seek to deliver meaningful results for patients, providers and the healthcare system as a whole while achieving significant ROI.

1. CMS, 13 June 2024. 'NHE Fact Sheet'
2. Blumenthal, D., Gumas, E. D., Shah, A., Gunja, M. Z., and Williams II, R. D., September 2024. 'Mirror, Mirror 2024: A Portrait of the Failing U.S. Health System'. The Commonwealth Fund
3. Dunn, A., Fernando, L., Liebman, E., and Godfrey J. M. 'A Direct Measure of Medical Innovation on Health Care Spending: A Condition-Specific Approach'. Bureau of Economic Analysis Working Paper Series, WP2023-10
4. Health Advances analysis of Evaluate Pharma data
5. Altarum Health Sector Economic Indicators, January 2024. 'How Health Care Employment Growth in December Capped Off a Historic Year of Job Creation in 2023'. Altarum
6. KFF, October 2023. '2023 Employer Health Benefits Survey'
7. Patel, N. and Singhal, S., January 2024. 'What to Expect in US Healthcare in 2024 and Beyond'. McKinsey & Company
8. McGough, M., Winger, A., Kurani, N., and Cox, C., October 2024. 'How much is health spending expected to grow?' KFF
9. Sertkaya, A., Beleche, T. and Jessup, A., 2024. 'Costs of Drug Development and Research Development Intensity in the US, 2000-2018'. JAMA Netw Open. 2024;7(6):e2415445
10. Kim, E., Yang, J., Park, S. and Shin, K., May 2023. 'Factors Affecting Success of New Drug Clinical Trials'. Therapeutic Innovation & Regulatory Science. 2023;57:737-750
11. Nguyen, K-L., September 2019. 'HIPAA: At What Cost?'. Medical Economics
12. Kane, L., January 2023. 'I Cry but No One Cares': Physician Burnout & Depression Report 2023. Medscape
13. Cutler, D. M., 2023. 'Health System Change in the Wake of COVID-19'. JAMA Health Forum. 2023;4(10):e234355
14. Reinsel, D., Gant, J. and Rydning, J., November 2018. 'The Digitization of the World: From Edge to Core'. IDC White Paper #US44413318
15. Sullivan, M., May 2018. 'Why EHR Data Interoperability is Such a Mess in 3 Charts'. Healthcare IT News
16. Adams, K., February 2024. 'Tools for Better Data Interoperability Are Here — But Providers Aren't Adopting Them'. MedCity News
17. Cigna Fact Sheet, 2021. 'One-Year Impact of COVID-19: Surging Use of Virtual and Behavioral Health'
18. Allied Market Research, November 2022. 'At-Home Testing Market Size, Share, Competitive Landscape and Trend Analysis Report, by Test Type, by Age Group, by Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031'



**Jo Natauri is the Founder of Invidia Capital Management.** She brings over 25 years of experience in the healthcare sector, including private equity investment, board membership, investment banking and operational leadership. Prior to launching Invidia Capital Management, Jo was the Global Head of Private Healthcare Investing at Goldman Sachs. During her tenure at Goldman Sachs, she led over \$9 billion in equity and structured capital investments and advised on more than \$250 billion in M&A transactions.